Roche Announces Internal Review Likely To Result In Staff, Program Cuts
This article was originally published in The Pink Sheet Daily
Executive Summary
Swiss pharma cites U.S. and EU health care spending constraints and regulatory setbacks as reasons for plan.
You may also be interested in...
Alnylam Shifts To Product-Focused Strategy As RNAi Platform Takes A Hit
Alnylam Pharmaceuticals' strategy announcement on Jan. 7 was “a transformation,” CEO John Maraganore said in an interview at the J.P. Morgan Healthcare Conference, emphasizing that he has “never been more excited” about the prospects for his company.
Alnylam Shifts To Product-Focused Strategy As RNAi Platform Takes A Hit
Alnylam Pharmaceuticals' strategy announcement on Jan. 7 was “a transformation,” CEO John Maraganore said in an interview at the J.P. Morgan Healthcare Conference, emphasizing that he has “never been more excited” about the prospects for his company.
Chugai To Remain Unscathed By Roche's Internal Restructuring And Cost-cutting Measures
TOKYO - Roche Group is in the process of reviewing and implementing a group-wide productivity and cost reduction program, but Japanese partner Chugai will not be directly impacted by the initiative, according to Roche's CEO